**PRODUCT:** SNX-2112  

**ALTERNATE NAME:** 2-[(trans-4-Hydroxycyclohexyl)amino]-4-[(2,3,4,5-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)benzamide; PF-04928473

**CATALOG #:** B2211-5,25  

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**

![SNX-2112 Structure](image)

**MOLECULAR FORMULA:** C_{23}H_{27}F_{3}N_{4}O_{3}

**MOLECULAR WEIGHT:** 464.48

**CAS NUMBER:** 908112-43-6

**APPEARANCE:** Crystalline solid

**SOLUBILITY:** DMSO (>50 mg/ml)

**PURITY:** ≥98% by HPLC

**STORAGE:** Store at -20 °C. Protect from light and light.

**DESCRIPTION:** SNX-2112 is a potent heat-shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. SNX-2112 selectively accumulates in tumors compared to normal tissues and binds to the N-terminal adenosine triphosphate binding site of Hsp90, inhibiting its activity. This results in the proteasomal degradation of oncogenic client proteins, which prevents signaling through these client proteins, induces apoptosis and inhibits tumor cell proliferation.


**RELATED PRODUCTS:**
- 17-AAG (Cat. No. 1774-1,5)
- EZSolution™ 17-AAG (Cat. No. 9495-1)
- BIIIB021 (Cat. No. 2291-5,25)
- 17-DMAG (Cat. No. 1776-1,5)
- Ganetespiib (Cat. No. 9459-5,25)
- Geldanamycin (Cat. No. 1564-1,5)
- KRIIBB11 (Cat. No. B1567-5,25)
- KW-2478 (Cat. No. B2188-5,25)
- NVP-AUY922 (Cat. No. 1591-1,5)
- NVP-BEP800 (Cat. No. B2198-1,5)
- PU-WS13 (Cat. No. 9442-5,25)
- SNX-2112 (Cat. No. B2211-5,25)
- XL-888 (Cat. No. 2654-1,5)

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**USAGE:** FOR RESEARCH USE ONLY! Not to be used in humans